WeVote
Log In

Bill

Bill

S 3047

Repeals section 3 of article 16 relating to the taxation of moneys, credits, securities and other intangible personal property in the state that is not employed in carrying on any business therein

2025 Regular Session Introduced by Jabari Brisport and 2 co-sponsors

Requires certain birthing centers, FQHCs, and prenatal/postpartum providers to evaluate symptomatic patients for pregnancy-related hypertensive disorders using evidence-based metho

OPINION REFERRED TO JUDICIARY
0
WeVote Research Nonpartisan
Bill Summary · S 3047

Summary — S-3047 (1R) — Preeclampsia / pregnancy‑related hypertensive disorder evaluations

Note: The bill metadata in the prompt (a title about repealing an Article 16 tax provision) appears to be erroneous and unrelated to the bill text provided. The text and committee report below concern requirements for evaluation, counseling, and treatment planning for pregnancy‑related hypertensive disorders (including preeclampsia). This summary describes the bill as reported by the Senate Health, Human Services and Senior Citizens Committee (1R, 3/3/2025).

Main purpose

Require certain New Jersey birthing centers, federally qualified health centers (FQHCs), and health care practitioners who provide prenatal or postpartum care (within 12 weeks after birth) to adopt policies to evaluate people who show symptoms of pregnancy‑related hypertensive disorders — including preeclampsia and postpartum preeclampsia — and to provide evidence‑based information and follow‑up care when appropriate.

Key provisions

  • Scope of entities covered

    • Licensed birthing centers, federally qualified health centers, and health care practitioners providing prenatal care or postpartum care within 12 weeks of birth.
    • Hospitals were removed from the scope by committee amendment.

  • Trigger and nature of evaluation

    • Require evaluation (the bill uses “evaluation” rather than “screening”) for hypertensive disorders related to pregnancy when a person shows symptoms and has not already been diagnosed in the current or recent pregnancy.
    • Evaluation tools and procedures must be based on best practices and guidance from the American College of Obstetricians and Gynecologists (ACOG) or another nationally recognized body.

  • Information, counseling, and follow‑up

    • Providers must give evidence‑based information on pregnancy‑related hypertensive disorders and warning signs/symptoms.
    • Providers must inform the person of the benefits of evaluation and that evaluation is recommended when symptoms occur; the person may decline evaluation (evaluations are permissive under the amended bill and may be declined without a written refusal).
    • If an evaluation yields a positive result, the provider must discuss results and develop an evidence‑based treatment plan to reduce risk.

  • Standards and oversight

    • Requirements tied to “nationally recognized evidence‑based treatment practices” rather than state‑developed guidelines.
    • Rulemaking: committee amendment makes rule adoption permissive for the Commissioner of Health but required for the State Board of Medical Examiners and any other regulatory boards that oversee health care practitioners.

  • Implementation timing and removed items

    • Effective 180 days after adoption (committee amendment).
    • Committee amendments removed prior provisions concerning hospitals, mandatory written refusals, home blood pressure monitoring, and a state preeclampsia education program.

Who is affected

  • Patients: pregnant people and people within 12 weeks postpartum who seek care and exhibit symptoms of hypertensive disorders (including postpartum preeclampsia).
  • Providers: licensed birthing centers, FQHCs, and health care practitioners offering prenatal or postpartum care within 12 weeks.
  • Regulatory boards: State Board of Medical Examiners and other boards regulating health practitioners will be required to adopt implementing rules.

Fiscal and administrative impact

  • Office of Legislative Services (OLS) fiscal estimate (8/13/2025) — Indeterminate:
    • NJ FamilyCare (State Medicaid) costs may increase if more or more intensive evaluations/counseling occur; amount indeterminate.
    • Increased Medicaid expenditures could be offset partially by increased federal matching funds (indeterminate).
    • Potential long‑term savings are possible if earlier detection/treatment reduces downstream costs.
    • Departments (Health, Human Services, Law & Public Safety boards) would incur indeterminate administrative costs, possibly absorbable within existing resources.

Procedural status (as reported)

  • Reported favorably with committee amendments by Senate Health, Human Services and Senior Citizens Committee — March 3, 2025 (Reprint SHH 3/3/25 1R).
  • Referred to Senate Budget & Appropriations Committee after committee report.
  • Previously referred to Judiciary for opinion (records indicate multiple referrals/requests for opinion).
  • Sponsored in the version text by Senator Renee C. Burgess and Senator Raj Mukherji.

Practical effect

If enacted, the bill would raise the standard for evaluating symptomatic pregnant and recently postpartum patients for hypertensive disorders across specified outpatient and birthing settings in New Jersey by requiring evidence‑based evaluation, patient education, and documented follow‑up treatment planning, while preserving patient choice to decline evaluation.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.